Hepatokine-Targeted Therapeutics for Modulating Metabolic Dysfunction in Type 2 Diabetes

Author Name : Hidoc internal team

Diabetology

Page Navigation

Abstract

Type 2 diabetes is a heterogeneous metabolic disorder characterized by insulin resistance, progressive beta-cell dysfunction, abnormal lipid handling, chronic low-grade inflammation, and dysregulated communication among metabolic organs. The liver is central to this network because it integrates nutrient flux, insulin signaling, lipid metabolism, bile acid biology, and endocrine communication through hepatokines. Hepatokines are liver-derived signaling proteins and mediators that influence glucose homeostasis, adipose tissue function, skeletal muscle insulin sensitivity, pancreatic beta-cell performance, and systemic inflammation. Abnormal secretion or activity of hepatokines such as fetuin-A, fetuin-B, fibroblast growth factor 21, selenoprotein P, angiopoietin-like protein 8, and insulin-like growth factor binding protein 2 has been associated with metabolic dysfunction, hepatic steatosis, cardiovascular risk, and progression of type 2 diabetes. Therapeutic strategies aimed at modifying hepatokine production, receptor signaling, or downstream pathways are therefore being investigated as mechanism-based approaches that may complement established glucose-lowering treatments. Current evidence is strongest for fibroblast growth factor 21 pathway agonism, while other hepatokine-directed interventions remain experimental. Translation into clinical practice will require careful assessment of efficacy, durability, safety, tissue specificity, and effects on liver disease and cardiovascular outcomes.

Introduction

Type 2 diabetes increasingly presents as a multisystem disorder rather than an isolated abnormality of blood glucose. Contemporary management emphasizes cardiovascular and renal risk reduction, weight control, treatment of metabolic dysfunction-associated steatotic liver disease, and prevention of microvascular complications. Within this framework, the liver has emerged as both a target and an endocrine regulator of metabolic health. Hepatocytes respond to nutritional status, insulin, glucagon, inflammatory signals, and lipid accumulation by releasing soluble mediators that alter the activity of distant organs.

Hepatokines provide a biologically plausible link between hepatic insulin resistance and systemic metabolic disease. Some hepatokines promote insulin resistance, inflammation, fibrosis, or ectopic lipid deposition, whereas others enhance energy expenditure, fatty acid oxidation, and glucose control. Their circulating concentrations may reflect disease severity, although associations do not necessarily establish causality. Research has consequently moved from observational biomarker studies toward therapeutic modulation of hepatokine pathways. The clinical importance of this field lies in its potential to address several components of metabolic dysfunction simultaneously, including hyperglycemia, obesity, steatohepatitis, dyslipidemia, and cardiometabolic risk.

Epidemiology / Disease Burden

Type 2 diabetes affects hundreds of millions of adults worldwide, and prevalence continues to rise because of population aging, urbanization, sedentary behavior, excess adiposity, and unequal access to preventive care. A substantial proportion of affected individuals have undiagnosed disease or are already developing complications at the time of diagnosis. The disorder imposes major costs through cardiovascular disease, chronic kidney disease, neuropathy, retinopathy, lower-extremity disease, reduced productivity, and premature mortality.

Hepatic metabolic dysfunction is common in people with type 2 diabetes. Excess hepatic fat, insulin resistance, elevated triglycerides, and abnormal aminotransferases frequently coexist, although liver enzymes may remain normal despite clinically important disease. Metabolic dysfunction-associated steatotic liver disease can progress to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. The shared biology of diabetes and liver disease has increased interest in hepatokines as markers of risk and as therapeutic targets. Their potential value is particularly relevant in patients with obesity, severe insulin resistance, dyslipidemia, or progressive hepatic fibrosis.

Pathophysiology

In healthy physiology, insulin suppresses hepatic gluconeogenesis and promotes glycogen synthesis, while coordinated lipid metabolism prevents excessive accumulation of triglycerides in hepatocytes. In type 2 diabetes, hepatic insulin resistance permits continued glucose production despite hyperinsulinemia. Increased delivery of fatty acids from adipose tissue, enhanced de novo lipogenesis, mitochondrial stress, endoplasmic reticulum stress, and altered bile acid signaling further disrupt hepatic function.

Fetuin-A is a liver-derived glycoprotein that can inhibit insulin receptor signaling and facilitate inflammatory responses associated with saturated fatty acids. Increased fetuin-A concentrations have been linked with insulin resistance, nonalcoholic fatty liver disease, and cardiovascular risk. Fetuin-B has been associated with hepatic steatosis and impaired glucose regulation, although its precise therapeutic relevance remains under investigation. Selenoprotein P may impair insulin sensitivity and exercise-related metabolic adaptation, and excessive activity of this pathway has been implicated in metabolic disease.

Fibroblast growth factor 21 is a stress-responsive hepatokine that acts through fibroblast growth factor receptors and the beta-Klotho coreceptor. It promotes fatty acid oxidation, improves insulin sensitivity, suppresses excessive hepatic lipogenesis, and may reduce body weight and liver fat. In obesity and diabetes, circulating fibroblast growth factor 21 can be elevated, suggesting a state of relative resistance rather than simple deficiency. Pharmacological agonists are designed to overcome this resistance through enhanced or prolonged receptor activation. Other candidates, including angiopoietin-like protein 8 and insulin-like growth factor binding protein 2, influence lipid trafficking, adipocyte biology, or glucose metabolism, but human evidence remains less mature.

Risk Factors

Risk factors for hepatokine dysregulation overlap with established risks for type 2 diabetes and liver disease. These include central obesity, visceral adiposity, diets rich in refined carbohydrates or saturated fat, low physical activity, sleep disruption, hypertension, atherogenic dyslipidemia, family history, advancing age, and genetic susceptibility. Certain ethnic groups experience diabetes and hepatic steatosis at lower body mass indices, reflecting differences in body composition and genetic risk. Alcohol exposure, medications, viral liver disease, and endocrine disorders may modify hepatic injury and must be considered when assessing liver-related metabolic abnormalities.

Hepatokine profiles may also be influenced by sex, renal function, inflammation, nutritional state, circadian biology, and the stage of liver fibrosis. These variables complicate the use of single hepatokine measurements as diagnostic or prognostic tests. A clinically useful risk assessment therefore requires integration of history, anthropometric measurements, laboratory data, comorbidities, and validated noninvasive fibrosis scores.

Clinical Features

Patients with hepatokine-associated metabolic dysfunction commonly present with hyperglycemia, increased waist circumference, hypertension, hypertriglyceridemia, low high-density lipoprotein cholesterol, or progressive weight gain. Many have no liver-specific symptoms. Fatigue or vague right upper-quadrant discomfort may occur, but these findings are nonspecific. Physical examination can reveal central obesity, acanthosis nigricans, hepatomegaly, or clinical features of advanced liver disease.

The clinical phenotype may include marked insulin resistance, difficulty achieving durable weight loss, recurrent dysglycemia, or discordance between normal aminotransferases and significant hepatic fibrosis. Cardiovascular disease remains the dominant cause of death in many people with type 2 diabetes, making risk assessment essential even when the principal therapeutic goal is glycemic control. Recognition of the liver-metabolic axis can help clinicians identify patients who require broader cardiometabolic management.

Diagnosis

Diagnosis of type 2 diabetes should follow accepted laboratory criteria using glycated hemoglobin, fasting plasma glucose, random plasma glucose in the presence of typical symptoms, or an oral glucose tolerance test when appropriate. Assessment should also include body mass index, waist circumference, blood pressure, fasting lipid profile, kidney function, urine albumin excretion, and evaluation for established complications.

Evaluation of hepatic involvement generally includes alanine aminotransferase, aspartate aminotransferase, platelet count, and review of alcohol intake and medication exposure. Noninvasive tools such as the fibrosis-4 index and vibration-controlled transient elastography can help identify patients at increased risk of advanced fibrosis. Ultrasound or other imaging may detect steatosis, but normal imaging or aminotransferases does not exclude clinically meaningful disease. Hepatokine assays are currently valuable mainly in research settings because standardized thresholds, analytical platforms, and evidence for improved patient outcomes are not yet established.

Treatment & Management

Current treatment remains centered on individualized lifestyle intervention and evidence-based glucose-lowering therapy. Calorie reduction, increased physical activity, resistance training, adequate sleep, and sustained weight loss can improve hepatic insulin sensitivity and alter hepatokine biology. Even modest weight reduction may decrease liver fat, while greater and sustained loss is more likely to improve steatohepatitis and fibrosis.

Metformin remains useful for glycemic management in appropriate patients, although it is not a dedicated treatment for advanced steatohepatitis. Sodium-glucose cotransporter 2 inhibitors reduce hyperglycemia, heart failure hospitalization, and kidney disease progression in selected populations. Glucagon-like peptide-1 receptor agonists and related incretin therapies produce substantial glucose lowering and weight loss and may improve hepatic steatosis. Pioglitazone can improve insulin sensitivity and histological features of steatohepatitis in selected patients, but risks such as weight gain, edema, and fracture require individualized assessment. Lipid-lowering therapy, blood pressure control, smoking cessation, vaccination, and management of cardiovascular risk are integral to care.

Hepatokine-targeted treatment is currently best regarded as an adjunctive or investigational strategy. Approaches include receptor agonism, neutralizing antibodies, antisense oligonucleotides, small interfering RNA, modulation of transcriptional regulators, and interventions that alter bile acid or nutrient-sensing pathways. Clinical implementation should await evidence demonstrating clinically meaningful improvements in glycemia, body weight, liver histology, cardiovascular outcomes, or renal outcomes with acceptable safety.

Recent Advances / Emerging Therapies

Fibroblast growth factor 21 analogues and receptor agonists are the most advanced hepatokine-based therapies. Early and mid-stage trials have reported improvements in triglycerides, liver fat, insulin sensitivity, body weight, and markers of liver injury. Some agents have also shown signals for improvement in steatohepatitis and fibrosis-related endpoints. Important limitations include gastrointestinal adverse effects, variable weight reduction, injection burden, uncertain long-term cardiovascular benefit, and the possibility that biochemical improvement may not translate into reduced clinical events.

Investigational therapies directed at selenoprotein P seek to reverse impaired exercise responsiveness and insulin resistance, but challenges include tissue specificity and the physiological roles of this protein in antioxidant defense. Fetuin-A inhibition is conceptually attractive because it may reduce insulin receptor antagonism and inflammatory signaling, yet broad suppression could produce unintended effects on mineral metabolism or vascular biology. Modulation of angiopoietin-like proteins may improve lipid partitioning, although the complexity of lipoprotein trafficking creates potential risks of hypertriglyceridemia or tissue-specific adverse effects. Combination therapies may ultimately be more effective than single-pathway interventions. For example, a hepatokine agonist could be combined with an incretin-based therapy, sodium-glucose cotransporter 2 inhibition, or a lipid-lowering agent to target complementary mechanisms. Precision medicine approaches using hepatic fat measurements, genetic profiles, inflammatory markers, and circulating hepatokine patterns may help identify patients most likely to benefit. However, durable safety data, standardized outcome definitions, and comparative trials against established therapies remain essential.

Guideline Recommendations

Current diabetes guidelines recommend a patient-centered approach that prioritizes individualized glycated hemoglobin targets, avoidance of hypoglycemia, weight management, and reduction of atherosclerotic cardiovascular, heart failure, and kidney risk. In people with established cardiovascular or kidney disease, therapies with proven outcome benefits should be considered independently of baseline glycated hemoglobin when clinically appropriate. Patients with obesity may benefit from pharmacological weight management or metabolic surgery according to accepted eligibility criteria.

Guideline-based liver assessment supports case finding for clinically significant fibrosis among people with diabetes or metabolic risk factors, beginning with simple noninvasive scores and progressing to elastography or specialist evaluation when indicated. Hepatokine concentrations should not currently replace validated diagnostic pathways. Clinicians should explain that emerging hepatokine therapies are not substitutes for lifestyle measures or established cardiometabolic treatment. Enrollment in well-designed clinical trials is appropriate when investigational therapies are available and ethical requirements are met.

Conclusion

Hepatokines represent an important biological interface between hepatic dysfunction and systemic metabolic disease in type 2 diabetes. Their effects on insulin signaling, lipid transport, inflammation, energy expenditure, and tissue communication provide a strong rationale for mechanism-based therapeutic development. Fibroblast growth factor 21 pathway agonism has generated the most encouraging clinical evidence, while therapies targeting fetuin-A, fetuin-B, selenoprotein P, angiopoietin-like proteins, and related pathways remain under investigation. At present, treatment should continue to emphasize weight reduction, physical activity, evidence-based glucose-lowering agents, cardiovascular and renal risk reduction, and structured evaluation for liver fibrosis. Future research must establish whether hepatokine-directed interventions improve patient-important outcomes, identify reliable biomarkers of response, and define safe combinations with existing therapies. Successful translation could advance precision management of diabetes by addressing the interconnected hepatic, metabolic, and inflammatory mechanisms that sustain disease progression.

Featured News
Featured Articles
Featured Events
Featured KOL Videos

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot